Galen Robotics raised $15 million to bring the robotic surgery platform to market

Galen Robotics raised $15 million to bring the robotic surgery platform to market

The company has developed a surgical robotic assistant that can be ready in less than 15 minutes

There are many benefits to using an assistive robot in surgery: due to its small size, it can go to places that humans cannot easily reach, while using high-resolution cameras to give surgeons a more accurate view of the surgery area. This has benefits for the patient: one study It found that robotic surgery reduced the chance of readmission by 52%, and reduced the prevalence of blood clots by 77%.

Unfortunately, there are a number of areas of surgery that this technology has not yet served, Dave Saunders, chief technology officer and co-founder of Galen Robotics, a Digital-Surgery-as-a-Service company, told VatorNews; includes sTissue surgeons often, perform narrow passage, minimally invasive procedures, and who need a surgical assistant that is optimized for body parts.

Here’s what Galen is giving them now: The company has developed a robotic surgical assistant that can be transported into the operating room and ready to go in less than 15 minutes to help surgeons with humanly difficult procedures.

“Our surgical robot is intended to help in areas where there are no other surgical robots for these surgeons performing these procedures. While there are many surgical robots on the market today, no robot can do all things, and all robots are designed around the A specific component is a step in a procedure, such as cutting the end of the femur for a knee implant, or around a combination of procedures on a part of the body, such as laparoscopic surgery in the abdomen,” Saunders said.

“Our goal is to meet some of the unmet needs that are currently evident in this growing industry.”

The company is ready to head to market as soon as possible, having recently submitted a new collaborative soft tissue surgery robot to the US Food and Drug Administration (FDA) for consideration, and it now has the new $15 million financing round from Ambix Healthcare Partners to help make this happen once this license is obtained.

To use Galen’s device, the surgeon takes one of the tools he was already using and attaches it to the robot’s arm to a tool adapter Galen designed. Then they grab the tool and use it as they normally would; The robot follows his hand, but the instrument is sturdier compared to a hand held instrument, and it can be held in place by the robot while the surgeon uses another instrument.

“This gives the surgeon a third hand that can move when needed and also ‘stability’ without feeling tired,” Saunders explained.

Once you are able to go to market, the company She will initially focus on laryngeal procedures, although she plans to do so It will expand the platform to include other areas, including otolaryngology, neurosurgery, spine, and cardiothoracic procedures.

Saunders said laryngeal and vocal cord surgery is the first indication that the company is seeking a permit because it provides a great opportunity to demonstrate the benefit of this platform.

“These procedures are performed with long instruments down the throat and are very challenging from the point of view of comfort and dexterity. If you then think about other types of micro-procedures that are also performed through small openings or incisions, using long instruments and a surgical microscope, you should be able on inferring benefits similar to what we expect to demonstrate with this first procedure.”

In addition to the surgical fields for which he creates solutions, Galen also differentiates himself from others in the robotic surgery space by deploying what he calls an on-demand business model, rather than Hospitals pay up front for capital equipment; This change was necessary due to the COVID-19 pandemic, which has caused hospital profits to plummet as elective surgeries are postponed.

“Most of the Medtech industry is currently driven by significant capital expenditures. These typically require a longer selling cycle and with post-Covid budget constraints it can be difficult for a lower revenue department to get the attention they need for new technology,” Saunders said. .

“We expect our paper use sales model to be more attractive in relation to the current economic constraints in hospitals. The specific design of our robot allows us to manufacture it at a much lower cost than most robots on the market today, and this allows us to handle our portable expenses when placing robots in hospitals and not book No revenue provided.

Series A helped complete the final robot prototype, submitting Galen to the FDA; The funding will also be used to build its team, including developing a clinical sales team, expanding engineering, developing augmented products, and developing surgeon training programs. company It currently has approximately 40 employees and plans to double that over the next 12 to 18 months.

The company has also not finished raising funds yet; To accommodate the expected demand for its technology, and to help manage the supply chain affected by COVID, the company has opened a second closing of its Series A funding round for more 5 million dollars.

“As we continue to develop this platform technology, we hope to see it used in multiple surgical departments and support surgeries in a variety of surgical procedures, where no other robotic technology exists today,” Saunders said.

“Ultimately, they should allow us to develop additional applications and robot extensions, which are targeted to specific actions, but can be more economical than you would normally expect in the industry, which is to build an entire robotic platform around a single action.”

#Galen #Robotics #raised #million #bring #robotic #surgery #platform #market

Leave a Comment

Your email address will not be published. Required fields are marked *